ClinicalTrials.gg
CompletedNCT00095199Updated Oct 15, 2012Results posted

Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer

A Phase 3 interventional study of Pemetrexed and Cetuximab in Non Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 67 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-10-15.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
939
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 33 under way, 12 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
5th of 224
939 · median 65
Started
2005
with 19 others
Phase 3
45 of 228
5 open now
Registered
8th of 228
by date
Lead sponsor
40 of 228
Eli Lilly and Company

Among the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment of the 224 interventional ones that give a count, is one of 20 that started in 2005, is one of 45 in phase 3, and was the 8th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This trial is a multicenter, open-label, randomized, Phase III study in patients with recurrent or progressive Non-Small Cell Lung Cancer (NSCLC) after failure of an initial platinum-based chemotherapy. Patients will receive either Docetaxel or Pemetrexed as chemotherapy at the investigator's choice. Within each chemotherapy group, patients will be randomized to receive Cetuximab plus chemotherapy or chemotherapy alone (Cetuximab \& Pemetrexed or Pemetrexed alone; Cetuximab \& Docetaxel or Docetaxel alone).

03

Conditions studied

  • Non Small Cell Lung Cancer

Keywords

  • Recurrent or Progressive Non-Small Cell Lung Cancer
  • Second-line therapy
  • Docetaxel
  • Pemetrexed
  • Cetuximab
  • Failed platinum-based therapy
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pathologic confirmation of , unresectable, or locally-advanced NSCLC.
  • Disease progression during or following one prior platinum-based chemotherapy regimen for advanced disease (stage IIIB or IV).
  • Bidimensionally .
  • performance status score of 60 to 100 at study entry.
  • The participant has tumor tissue available for immunohistochemical determination of epidermal growth factor (EGFR) expression.
  • Adequate recovery from recent surgery, chemotherapy, and radiation therapy. At least 4 weeks must have elapsed from major surgery, prior chemotherapy, prior treatment with an agent, or prior radiation therapy (palliative radiation therapy is allowed).
  • Accessible for treatment and follow-up. Participants enrolled in this trial must be treated at the participating center.
  • Women of (WOCBP) and fertile men with partners of childbearing potential must be using an adequate method of .
  • WOCBP must have a negative serum or urine pregnancy test.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breastfeeding.
  • Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of .
  • A serious uncontrolled medical disorder that would impair the ability of the patient to receive protocol therapy.
  • Symptomatic or uncontrolled in the brain. Participants receiving a for will be excluded, but those receiving anticonvulsants will be eligible.
  • Uncontrolled pleural effusion or ascites.
  • Peripheral neuropathy greater than grade 2, as assessed by the National Cancer Institutes-Common Toxicity Criteria Adverse Events (), Version 3.0.
  • Any concurrent other than basal cell skin cancer, or carcinoma in situ of the cervix. Patients with a previous malignancy, but without evidence of disease for greater than or equal 3 years will be allowed to enter the trial.
  • More than one prior chemotherapy regimen for advanced disease.
  • Inadequate hematologic function defined by an (ANC) \<1,500/mm3, a count \<100,000/mm3, and a level \<9 g/dL. Red blood cell transfusions are not permitted within 7 days of receiving cetuximab, docetaxel, or pemetrexed.
  • Inadequate hepatic function, defined by a total level >1.5 times the (ULN), (AST) and alanine aminotransferase (ALT) levels >2.5 times the ULN (greater than or equal to 5 times the ULN if known liver metastases), and an alkaline phosphatase level >5.0 times the ULN.
  • Inadequate renal function defined by a serum creatinine level >1.5 times the ULN.
  • Prior treatment with cetuximab, or any other epidermal growth factor receptor inhibitors, including tyrosine kinase inhibitors, such as gefitinib or erlotinib. Participants must not have received prior chimerized or murine monoclonal antibody therapy. Prior treatment with other monoclonal antibodies targeting receptors other than the EGFR is permitted >30 days prior to randomization.
  • Prior treatment with docetaxel or pemetrexed therapy.
  • Inability or unwillingness to take folic acid or vitamin B12 supplementation.
  • Inability or unwillingness to interrupt nonsteroidal anti-inflammatory drugs (NSAIDs) for a 5-day period (8-day period for long-acting agents such as piroxicam). Aspirin will be permitted during the study.
  • Patients (including prisoners) who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (eg, infectious disease) illness.
  • Prior treatment with an experimental drug or medical device within 30 days of randomization.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
939 participants (actual)

Study arms

  • Experimental
    Cetuximab & Pemetrexed

    Drug: Pemetrexed · Biological: Cetuximab

  • Active comparator
    Pemetrexed

    Drug: Pemetrexed

  • Experimental
    Cetuximab & Docetaxel

    Biological: Cetuximab · Drug: Docetaxel

  • Active comparator
    Docetaxel

    Drug: Docetaxel

Interventions

  • Pemetrexed 500 mg/m\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.

    Also known as: Alimta, LY231514

  • BiologicalCetuximab

    Cetuximab 400/250 mg/m\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity.

    Also known as: Erbitux, LY2939777

  • Docetaxel 75 mg/m\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time from randomization until the date of progressive disease (PD) or death from any cause. Participants who were alive and without progression were censored at the date of their last tumor assessment. PFS was assessed by the independent review committee (IRC) in the Pemetrexed group (Cetuximab \& Pemetrexed versus Pemetrexed) and by the investigator in the Docetaxel group (Cetuximab \& Docetaxel versus Docetaxel).

    Time frame: Randomization to progression of disease or death due to any cause up to 59.6 months

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from randomization to death. Participants without a date of death were censored on the last date participants were known to be alive, or lost to follow-up.

    Time frame: Randomization to the date of death from any cause up to 72.8 months

  2. Proportion of Randomized Participants With the Best Overall Response (OR) of Partial Response (PR) or Complete Response (CR) (Overall Response Rate [ORR])

    The best overall response rate (ORR) was the proportion of randomized participants with a best OR of CR or PR, according to modified World Health Organization (WHO) guidelines. It was calculated as the total number of participants with CR or PR divided by the total number of participants treated in that arm. Participants with no post-baseline evaluation were considered as non-responders. The tumor response was assessed by the independent review committee (IRC) in the Pemetrexed group and by the investigator in the Docetaxel group.

    Time frame: Randomization until progression of disease or death from any cause up to 59.6 months

  3. Proportion of Randomized Participants With Best Overall Response (OR) of Partial Response (PR), Complete Response (CR), or Stable Disease (SD)

    The disease control rate (DCR) was the proportion of randomized participants with a best OR of CR, PR or SD according to modified World Health Organization (WHO) guidelines. It was calculated as the total number of participants with CR, PR or SD divided by the total number of participants randomized in that arm. The tumor response was assessed by the independent review committee (IRC) in the Pemetrexed group and by the investigator in the Docetaxel group.

    Time frame: Randomization to progression of disease or death due to any cause up to 59.6 months

  4. Percentage of Participants With Symptomatic Response (Symptom Response Rates) Using the Lung Cancer Subscale (LCS) Scores of Functional Assessment of Cancer Therapy for Participants With Lung Cancer (FACT-L)

    The FACT-LCS is a set of 7 questions to inventory problems specific to lung cancer symptoms. Participants rate each item on a 5-point Likert-type scale from 0 (not at all) to 4 (very much). Scores range from 0-28 and higher score indicates fewer symptoms. Symptom response (improvement) was defined as ≥2 point increase from baseline in the 7-item LCS score that was maintained for 2 consecutive assessments at least 3 weeks, and not \>5 weeks apart for participants, whose baseline LCS score was ≤26. Symptom response rate was the percentage of participants with symptomatic response.

    Time frame: At baseline, every 3 weeks and 30 days after end of therapy up to 50 months

  5. Time to Symptomatic Progression

    The FACT-LCS (see description in Outcome measure 5) inventories problems specific to lung cancer symptoms. Using this Scale, Symptom progression = a ≥ 2 point decrease from baseline in LCS score maintained for 2 consecutive assessments ≥3 weeks, and \<5 weeks, apart. The symptom progression date = the first of 2 consecutive assessments with a ≥2 point decline. Time to symptomatic progression = the time from randomization to the symptom progression date. For participants with no symptom progression, time to symptomatic progression was censored the date of last symptom assessment.

    Time frame: Randomization until symptomatic progression up to 48.3 months

  6. Duration of Overall Response (OR)

    The duration of response, in participants with best OR of complete response (CR) or partial response (PR), was measured from the date criteria are met for CR/PR (not confirmation date, whichever was first recorded), until the first occurrence date that the criteria of progressive disease (PD) was met, or death. Participants who were alive and without progression were censored at the date of their last independent review committee (IRC) tumor assessment. The tumor response and progression were assessed by the IRC in the Pemetrexed group and by the investigator in the Docetaxel group.

    Time frame: Time of first occurrence of either (PR) or (CR) to the first date of progressive disease or death up to 32.5 months

  7. Number of Participants With Common Toxicity Criteria (CTC) Grade 3 or 4 Toxicities

    National Cancer Institutes-Common Toxicity Criteria version 3.0 was used by investigators to assess participant toxicities. Mapping of investigator verbatim terms to CTCAE terms was done by the sponsor/designee using CTCAE v4.0. Participants reported had grade 3 or 4 toxicities (or both potentially). Grade 3 AEs: severe or medically significant but not immediately life-threatening;hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 AEs: life-threatening consequences; urgent intervention indicated.

    Time frame: Time from first dose to 30 days after last dose of study therapy up to 28.3 months for Cetuximab & Pemetrexed (versus Pemetrexed alone) and up to 54.3 months for Cetuximab + Docetaxel (versus Docetaxel alone)

07

Results

Posted Oct 15, 2012

Participant flow

Participant flow — Overall Study
MilestoneCetuximab & PemetrexedPemetrexedCetuximab and DocetaxelDocetaxel
Started302304167166
Completed662723
Not completed296242160143
Withdrew: Adverse event40222611
Withdrew: Progressive disease21317910598
Withdrew: Death106119
Withdrew: Withdrawal by subject21161322
Withdrew: Protocol violation4420
Withdrew: Liver function test results elevated0011
Withdrew: Surgery needed could not start in 7 days0010
Withdrew: Physician decision5611
Withdrew: Not eligible1701
Withdrew: Started palliative radiotherapy1000
Withdrew: Started radiotherapy regimen0100
Withdrew: Primary tumor removed in other surgery0100
Withdrew: Data inadvertently lost by site1000

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS was defined as the time from randomization until the date of progressive disease (PD) or death from any cause. Participants who were alive and without progression were censored at the date of their last tumor assessment. PFS was assessed by the independent review committee (IRC) in the Pemetrexed group (Cetuximab \& Pemetrexed versus Pemetrexed) and by the investigator in the Docetaxel group (Cetuximab \& Docetaxel versus Docetaxel).

Time frame:
Randomization to progression of disease or death due to any cause up to 59.6 months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsCetuximab & PemetrexedPemetrexedCetuximab & DocetaxelDocetaxel
Progression Free Survival (PFS)2.89 (2.69 to 3.22)2.76 (2.53 to 3.29)2.37 (1.61 to 2.89)1.54 (1.45 to 2.50)
Statistical analysis
  • Cetuximab & Pemetrexed vs Pemetrexed · Log Rank · p = 0.756 (The 2-sided unstratified log-rank test was employed at the 5% significance level.) · Hazard ratio (hr): 1.03 · 95% CI 0.87 to 1.21Kaplan-Meier method estimated median PFS time. HR was calculated with unstratified Cox proportional hazards model. HR\<1 favours Cetuximab arm
  • Cetuximab & Docetaxel vs Docetaxel · Log Rank · p = 0.391 (The 2-sided unstratified log-rank test was employed at the 5% significance level.) · Hazard ratio (hr): 0.91 · 95% CI 0.73 to 1.13Kaplan-Meier method estimated median PFS time. HR was calculated with unstratified Cox proportional hazards model. HR\<1 favours Cetuximab arm
SecondaryOverall Survival (OS)

OS was defined as the time from randomization to death. Participants without a date of death were censored on the last date participants were known to be alive, or lost to follow-up.

Time frame:
Randomization to the date of death from any cause up to 72.8 months
Reported as:
Median · months
Overall Survival (OS)
monthsCetuximab & PemetrexedPemetrexedCetuximab & DocetaxelDocetaxel
Overall Survival (OS)6.93 (6.28 to 7.85)7.79 (6.77 to 8.41)5.75 (4.73 to 8.31)8.15 (6.11 to 9.20)
Statistical analysis
  • Cetuximab & Pemetrexed vs Pemetrexed · Log Rank · p = 0.864 (The 2-sided unstratified log-rank test was employed at the 5% significance level) · Hazard ratio (hr): 1.01 · 95% CI 0.86 to 1.20Kaplan-Meier method estimated median OS time. HR was calculated with unstratified Cox proportional hazards model. HR\<1 favors Cetuximab arm
  • Cetuximab & Docetaxel vs Docetaxel · Log Rank · p = 0.307 (The 2-sided unstratified log-rank test was employed at the 5% significance level.) · Hazard ratio (hr): 1.13 · 95% CI 0.90 to 1.41Kaplan-Meier method estimated median OS time. HR was calculated with unstratified Cox proportional hazards model. HR\<1 favors Cetuximab arm
SecondaryProportion of Randomized Participants With the Best Overall Response (OR) of Partial Response (PR) or Complete Response (CR) (Overall Response Rate [ORR])

The best overall response rate (ORR) was the proportion of randomized participants with a best OR of CR or PR, according to modified World Health Organization (WHO) guidelines. It was calculated as the total number of participants with CR or PR divided by the total number of participants treated in that arm. Participants with no post-baseline evaluation were considered as non-responders. The tumor response was assessed by the independent review committee (IRC) in the Pemetrexed group and by the investigator in the Docetaxel group.

Time frame:
Randomization until progression of disease or death from any cause up to 59.6 months
Reported as:
Number · proportion of participants
Proportion of Randomized Participants With the Best Overall Response (OR) of Partial Response (PR) or Complete Response (CR) (Overall Response Rate [ORR])
proportion of participantsCetuximab & PemetrexedPemetrexedCetuximab & DocetaxelDocetaxel
Proportion of Randomized Participants With the Best Overall Response (OR) of Partial Response (PR) or Complete Response (CR) (Overall Response Rate [ORR])0.066 (0.038 to 0.095)0.043 (0.020 to 0.066)0.078 (0.037 to 0.118)0.066 (0.028 to 0.104)
Statistical analysis
  • Cetuximab & Pemetrexed vs Pemetrexed · Mantel Haenszel · p = 0.200 (The 2-sided unstratified Mantel Haenszel test was employed at the 5% significance level.) · Odds ratio (or): 1.59 · 95% CI 0.78 to 3.26HR\<1 favors Cetuximab arm
  • Cetuximab & Docetaxel vs Docetaxel · Mantel Haenszel · p = 0.683 (The 2-sided unstratified Mantel Haenszel test was employed at the 5% significance level.) · Odds ratio (or): 1.19 · 95% CI 0.52 to 2.74HR\<1 favors Cetuximab arm
SecondaryProportion of Randomized Participants With Best Overall Response (OR) of Partial Response (PR), Complete Response (CR), or Stable Disease (SD)

The disease control rate (DCR) was the proportion of randomized participants with a best OR of CR, PR or SD according to modified World Health Organization (WHO) guidelines. It was calculated as the total number of participants with CR, PR or SD divided by the total number of participants randomized in that arm. The tumor response was assessed by the independent review committee (IRC) in the Pemetrexed group and by the investigator in the Docetaxel group.

Time frame:
Randomization to progression of disease or death due to any cause up to 59.6 months
Reported as:
Number · proportion of participants
Proportion of Randomized Participants With Best Overall Response (OR) of Partial Response (PR), Complete Response (CR), or Stable Disease (SD)
proportion of participantsCetuximab & PemetrexedPemetrexedCetuximab & DocetaxelDocetaxel
Proportion of Randomized Participants With Best Overall Response (OR) of Partial Response (PR), Complete Response (CR), or Stable Disease (SD)0.522 (0.465 to 0.578)0.480 (0.424 to 0.536)0.335 (0.264 to 0.407)0.253 (0.187 to 0.319)
Statistical analysis
  • Cetuximab & Pemetrexed vs Pemetrexed · Mantel Haenszel · p = 0.310 (The 2-sided unstratified Mantel Haenszel test was employed at the 5% significance level.) · Odds ratio (or): 1.18 · 95% CI 0.86 to 1.62HR\<1 favors Cetuximab arm
  • Cetuximab & Docetaxel vs Docetaxel · Mantel Haenszel · p = 0.100 (The 2-sided unstratified Mantel Haenszel test was employed at the 5% significance level.) · Odds ratio (or): 1.49 · 95% CI 0.93 to 2.40HR\<1 favors Cetuximab arm
SecondaryPercentage of Participants With Symptomatic Response (Symptom Response Rates) Using the Lung Cancer Subscale (LCS) Scores of Functional Assessment of Cancer Therapy for Participants With Lung Cancer (FACT-L)

The FACT-LCS is a set of 7 questions to inventory problems specific to lung cancer symptoms. Participants rate each item on a 5-point Likert-type scale from 0 (not at all) to 4 (very much). Scores range from 0-28 and higher score indicates fewer symptoms. Symptom response (improvement) was defined as ≥2 point increase from baseline in the 7-item LCS score that was maintained for 2 consecutive assessments at least 3 weeks, and not \>5 weeks apart for participants, whose baseline LCS score was ≤26. Symptom response rate was the percentage of participants with symptomatic response.

Time frame:
At baseline, every 3 weeks and 30 days after end of therapy up to 50 months
Reported as:
Number · percentage of participants
Percentage of Participants With Symptomatic Response (Symptom Response Rates) Using the Lung Cancer Subscale (LCS) Scores of Functional Assessment of Cancer Therapy for Participants With Lung Cancer (FACT-L)
percentage of participantsCetuximab & PemetrexedPemetrexedCetuximab & DocetaxelDocetaxel
Percentage of Participants With Symptomatic Response (Symptom Response Rates) Using the Lung Cancer Subscale (LCS) Scores of Functional Assessment of Cancer Therapy for Participants With Lung Cancer (FACT-L)17.1 (12.7 to 21.6)22.9 (17.9 to 27.8)17.3 (11.3 to 23.4)13.5 (8.2 to 18.9)
Statistical analysis
  • Cetuximab & Pemetrexed vs Pemetrexed · Mantel Haenszel · p = 0.091 (The 2-sided unstratified Mantel Haenszel test was employed at the 5% significance level.) · Odds ratio (or): 0.70 · 95% CI 0.46 to 1.06HR\<1 favors Cetuximab arm
  • Cetuximab & Docetaxel vs Docetaxel · Mantel Haenszel · p = 0.361 (The 2-sided unstratified Mantel Haenszel test was employed at the 5% significance level.) · Odds ratio (or): 1.34 · 95% CI 0.72 to 2.50HR\<1 favors Cetuximab arm
SecondaryTime to Symptomatic Progression

The FACT-LCS (see description in Outcome measure 5) inventories problems specific to lung cancer symptoms. Using this Scale, Symptom progression = a ≥ 2 point decrease from baseline in LCS score maintained for 2 consecutive assessments ≥3 weeks, and \<5 weeks, apart. The symptom progression date = the first of 2 consecutive assessments with a ≥2 point decline. Time to symptomatic progression = the time from randomization to the symptom progression date. For participants with no symptom progression, time to symptomatic progression was censored the date of last symptom assessment.

Time frame:
Randomization until symptomatic progression up to 48.3 months
Reported as:
Median · months
Time to Symptomatic Progression
monthsCetuximab & PemetrexedPemetrexedCetuximab & DocetaxelDocetaxel
Time to Symptomatic ProgressionNA (NA to NA)NA (NA to NA)NA (7.00 to NA)NA (NA to NA)
Statistical analysis
  • Cetuximab & Pemetrexed vs Pemetrexed · Log Rank · p = 0.472 (The 2-sided unstratified log-rank test was employed at the 5% significance level.) · Hazard ratio (hr): 1.16 · 95% CI 0.77 to 1.74Kaplan-Meier estimated time to symptomatic progression. HR was calculated using unstratified Cox proportional hazards model. HR\<1 favors Cetuximab arm
  • Cetuximab & Docetaxel vs Docetaxel · Log Rank · p = 0.272 (The 2-sided unstratified log-rank test was employed at the 5% significance level.) · Hazard ratio (hr): 0.73 · 95% CI 0.42 to 1.27Kaplan-Meier estimated time to symptomatic progression. HR was calculated using unstratified Cox proportional hazards model. HR\<1 favors Cetuximab arm
SecondaryDuration of Overall Response (OR)

The duration of response, in participants with best OR of complete response (CR) or partial response (PR), was measured from the date criteria are met for CR/PR (not confirmation date, whichever was first recorded), until the first occurrence date that the criteria of progressive disease (PD) was met, or death. Participants who were alive and without progression were censored at the date of their last independent review committee (IRC) tumor assessment. The tumor response and progression were assessed by the IRC in the Pemetrexed group and by the investigator in the Docetaxel group.

Time frame:
Time of first occurrence of either (PR) or (CR) to the first date of progressive disease or death up to 32.5 months
Reported as:
Median · months
Duration of Overall Response (OR)
monthsCetuximab & PemetrexedPemetrexedCetuximab & DocetaxelDocetaxel
Duration of Overall Response (OR)4.17 (2.92 to 5.45)6.93 (3.98 to 16.36)5.36 (2.73 to 6.93)5.39 (3.12 to 7.16)
Statistical analysis
  • Cetuximab & Pemetrexed vs Pemetrexed · Log Rank · p = 0.236 (The 2-sided unstratified log-rank test was employed at the 5% significance level.) · Hazard ratio (hr): 1.58 · 95% CI 0.74 to 3.36The Kaplan-Meier method estimated duration of response. HR was calculated using unstratified Cox proportional hazards model. HR\<1 favors Cetuximab arm
  • Cetuximab & Docetaxel vs Docetaxel · Log Rank · p = 0.887 (The 2-sided unstratified log-rank test was employed at the 5% significance level.) · Hazard ratio (hr): 0.96 · 95% CI 0.42 to 2.18The Kaplan-Meier method estimated duration of response. HR was calculated using unstratified Cox proportional hazards model. HR\<1 favors Cetuximab arm
SecondaryNumber of Participants With Common Toxicity Criteria (CTC) Grade 3 or 4 Toxicities

National Cancer Institutes-Common Toxicity Criteria version 3.0 was used by investigators to assess participant toxicities. Mapping of investigator verbatim terms to CTCAE terms was done by the sponsor/designee using CTCAE v4.0. Participants reported had grade 3 or 4 toxicities (or both potentially). Grade 3 AEs: severe or medically significant but not immediately life-threatening;hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 AEs: life-threatening consequences; urgent intervention indicated.

Time frame:
Time from first dose to 30 days after last dose of study therapy up to 28.3 months for Cetuximab & Pemetrexed (versus Pemetrexed alone) and up to 54.3 months for Cetuximab + Docetaxel (versus Docetaxel alone)
Reported as:
Number · participants
Number of Participants With Common Toxicity Criteria (CTC) Grade 3 or 4 Toxicities
participantsCetuximab & PemetrexedPemetrexedCetuximab + DocetaxelDocetaxel
Number of Participants With Common Toxicity Criteria (CTC) Grade 3 or 4 Toxicities17914311297

Adverse events

Collected over Randomization to 30 days after study therapy up to 72.8 months for Cetuximab & Pemetrexed (versus just Pemetrexed) and up to 64.3 months for Cetuximab + Docetaxel (versus just Docetaxel). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cetuximab & Pemetrexed—119/292 (40.8%)289/292 (99%)
Pemetrexed—86/289 (29.8%)281/289 (97.2%)
Cetuximab and Docetaxel—84/159 (52.8%)159/159 (100%)
Docetaxel—60/149 (40.3%)147/149 (98.7%)
Most frequent serious events
Showing 10 of 223
Most frequent serious events
EventCetuximab & PemetrexedPemetrexedCetuximab and DocetaxelDocetaxel
DehydrationMetabolism and nutrition disorders11/2926/28917/1594/149
Febrile neutropeniaBlood and lymphatic system disorders2/2924/28913/15911/149
DyspnoeaRespiratory, thoracic and mediastinal disorders14/29211/28912/1596/149
PneumoniaInfections and infestations16/29217/2899/15910/149
NeutropeniaBlood and lymphatic system disorders4/2924/28910/1593/149
PyrexiaGeneral disorders7/2925/28910/1593/149
Deep vein thrombosisVascular disorders5/2920/2898/1592/149
Pleural effusionRespiratory, thoracic and mediastinal disorders9/2923/2894/1597/149
HaemoptysisRespiratory, thoracic and mediastinal disorders1/2922/2897/1593/149
Respiratory failureRespiratory, thoracic and mediastinal disorders7/2922/2897/1593/149
Most frequent other events
Showing 10 of 67
Most frequent other events
EventCetuximab & PemetrexedPemetrexedCetuximab and DocetaxelDocetaxel
Dermatitis acneiformSkin and subcutaneous tissue disorders223/2925/289100/1594/149
FatigueGeneral disorders158/292133/28988/15974/149
NeutropeniaBlood and lymphatic system disorders32/29232/28974/15946/149
DiarrhoeaGastrointestinal disorders81/29236/28963/15922/149
NauseaGastrointestinal disorders112/29289/28953/15938/149
Decreased appetiteMetabolism and nutrition disorders86/29258/28954/15945/149
StomatitisGastrointestinal disorders54/29221/28953/15923/149
DyspnoeaRespiratory, thoracic and mediastinal disorders66/29260/28943/15938/149
ConstipationGastrointestinal disorders75/29260/28941/15925/149
AnaemiaBlood and lymphatic system disorders70/29264/28940/15935/149

Baseline characteristics

Age Continuous
Age Continuous(years)Cetuximab & PemetrexedPemetrexedCetuximab & DocetaxelDocetaxelTotal
Mean62.8 ± 10.064.0 ± 9.463.6 ± 9.463.9 ± 9.263.5 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Cetuximab & PemetrexedPemetrexedCetuximab & DocetaxelDocetaxelTotal
Female1281167573392
Male1731889293546
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Cetuximab & PemetrexedPemetrexedCetuximab & DocetaxelDocetaxelTotal
White268265146141820
Black or African American2524132082
Asian365216
Hispanic482216
Unknown or Not Reported11114
Region of Enrollment
Region of Enrollment(participants)Cetuximab & PemetrexedPemetrexedCetuximab & DocetaxelDocetaxelTotal
United States265270152151838
Canada36341515100
Epidermal growth factor receptor (EGFR) by immunohistochemistry
Epidermal growth factor receptor (EGFR) by immunohistochemistry(participants)Cetuximab & PemetrexedPemetrexedCetuximab & DocetaxelDocetaxelTotal
+136351319103
+246532634159
+31181087258356
02132121075
Missing80764445245
Karnofsky Performance Status
Karnofsky Performance Status(participants)Cetuximab & PemetrexedPemetrexedCetuximab & DocetaxelDocetaxelTotal
60121421139
7035352114105
80103915557306
901011167464355
10048471418127
Missing/unknown21126
Pathological Diagnosis
Pathological Diagnosis(participants)Cetuximab & PemetrexedPemetrexedCetuximab & DocetaxelDocetaxelTotal
Adenocarcinoma1611859983528
Large cell carcinoma1977336
All other non-squamous diagnoses45412029135
Squamous cell carcinoma76714151239
08

Study locations

67 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Birmingham, Alabama 35294, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montgomery, Alabama 36106, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Phoenix, Arizona 85012, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tucson, Arizona 85715, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tuscon, Arizona 85704, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Greenbrae, California 94904, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    La Jolla, California 92093, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Denver, Colorado 80218, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stamford, Connecticut 06902, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Trumbull, Connecticut 06611, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jacksonville, Florida 32256, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lake Worth, Florida 33461, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    West Palm Beach, Florida 33401, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Athens, Georgia 30607, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Atlanta, Georgia 30341, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Augusta, Georgia 30901, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chicago, Illinois 60674, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Indianapolis, Indiana 46227, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Overland Park, Kansas 66210, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wichita, Kansas 67214, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Metairie, Louisiana 70006, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bethesda, Maryland 20817, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Frederick, Maryland 21701, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kalamazoo, Michigan 49048, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mount Clemens, Michigan 48043, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Minneapolis, Minnesota 55404, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St Louis Park, Minnesota 55416, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St Joseph, Missouri 64507, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Billings, Montana 59101, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Las Vegas, Nevada 89169, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cherry Hill, New Jersey 08003, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Albany, New York 12208, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rochester, New York 14623, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cary, North Carolina 27518, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Concord, North Carolina 28025, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    High Point, North Carolina 27262, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cincinnati, Ohio 45267, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Columbus, Ohio 43215, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tulsa, Oklahoma 74136, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Eugene, Oregon 97401, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Portland, Oregon 97239, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dunmore, Pennsylvania 18512, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kingston, Pennsylvania 18704, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Philadelphia, Pennsylvania 19114, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Greenville, South Carolina 29605, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hilton Head Island, South Carolina 29926, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mt. Pleasant, South Carolina 29464, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Memphis, Tennessee 38138, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bedford, Texas 76022, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75246, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Grapevine, Texas 76051, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Houston, Texas 77030, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mesquite, Texas 75150, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sugar Land, Texas 77479, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tyler, Texas 75702, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salt Lake City, Utah 84106, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Colchester, Vermont 05446, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Norfolk, Virginia 23502, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Richmond, Virginia 23249, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seattle, Washington 98133, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vancouver, Washington 98684, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Calgary, Alberta T2N 4N2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vancouver, British Columbia V5Z 4E6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ottawa, Ontario K1H 8L6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montreal, Quebec H2L 4M1, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sainte-Foy, Quebec G1V 4G2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St-Jerome, Quebec J7Z 5T3, Canada
09

References and documents

Publications

  • Kim ES, Neubauer M, Cohn A, Schwartzberg L, Garbo L, Caton J, Robert F, Reynolds C, Katz T, Chittoor S, Simms L, Saxman S. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol. 2013 Dec;14(13):1326-36. doi: 10.1016/S1470-2045(13)70473-X. Epub 2013 Nov 12. Erratum In: Lancet Oncol. 2014 Jan;15(1):e4. PubMed 24231627 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2004
First posted
Nov 2, 2004
Start
Jan 2005
Primary completionActual
Jul 2011
CompletionActual
Jul 2011
Results first posted
Oct 15, 2012
Last update
Oct 15, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00095199
Responsible party
Sponsor
First posted
Nov 2, 2004
Start date
Jan 2005
Primary completion
Jul 2011
Completion
Jul 2011
Results posted
Oct 15, 2012
Last update
Oct 15, 2012

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Cetuximab · Docetaxel

Start the discussion